April 3, 2020 09:33 AM EDTUpdated 11:46 AM

A small, obscure biotech just won big with their IPO. In this market. Are you kidding me?

How could a small, largely unknown biotech that emerged from stealth mode just months ago with early-stage cancer programs jump onto Wall Street in the …

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE

A small, obscure biotech just won big with their IPO. In this market. Are you kidding me?

This article is available only to Premium subscribers

Beam discloses first clinical data on base-edited sickle cell therapy, one patient death

Viking CEO on ‘shocking’ market reaction to oral obesity data, preparing for Phase 3

Sanofi reveals positive data for BTK inhibitor from $3.7B Principia takeover

Vertex makes money from sickle cell therapy Casgevy

Sana narrows focus again to zero in on diabetes and autoimmune disease

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

A small, ob­scure biotech just won big with their IPO. In this mar­ket. Are you kid­ding me?

This article is available only to Premium subscribers

Beam dis­clos­es first clin­i­cal da­ta on base-edit­ed sick­le cell ther­a­py, one pa­tient death

Viking CEO on ‘shock­ing’ mar­ket re­ac­tion to oral obe­si­ty da­ta, prepar­ing for Phase 3

Sanofi re­veals pos­i­tive da­ta for BTK in­hibitor from $3.7B Prin­cip­ia takeover

Ver­tex makes mon­ey from sick­le cell ther­a­py Cas­gevy

Sana nar­rows fo­cus again to ze­ro in on di­a­betes and au­toim­mune dis­ease

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A small, obscure biotech just won big with their IPO. In this market. Are you kidding me?

Beam discloses first clinical data on base-edited sickle cell therapy, one patient death

Viking CEO on ‘shocking’ market reaction to oral obesity data, preparing for Phase 3

Sanofi reveals positive data for BTK inhibitor from $3.7B Principia takeover

Vertex makes money from sickle cell therapy Casgevy

Sana narrows focus again to zero in on diabetes and autoimmune disease

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks